Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Lucía López‐Anglada, Roberto Maldonado et al.|Journal of Clinical Oncology|2019Cited by 279
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaLaura Rosiñol, Joan Bladé, Albert Oriol et al.|Blood|2019Cited by 218
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortalityJoaquín Martínez‐López, Jesús F. San Miguel, María‐Victoria Mateos et al.|Blood Cancer Journal|2020Cited by 78
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myelomaLaura Rosiñol, Joan Bladé, Albert Oriol et al.|Blood|2023Cited by 62
Mass spectrometry vs immunofixation for treatment monitoring in multiple myelomaNoemí Puig, María‐Victoria Mateos, María-Teresa Contreras et al.|Blood Advances|2022Cited by 53